medline.ch Onkologie Urologische Tumoren

	An efficient automated approach for accumulated dose estimation in prostate cancer radiotherapy. Phys Imaging Radiat Oncol Grohmann M, Krug D, Baehr A, Petersen C, Todorovic M, Schäfer S, Böckelmann LC, Gargioni E. PMID: 41853125 [PubMed - in process]
	Chromatin regulators TOP2A and PPARGC1A stratify prostate cancer risk and reveal TOP2A-driven progression via PI3K/AKT pathway. Chin J Cancer Res Wang Z, Wang J, Chen S, Wu R, Tuo Z, Ye L, Yoo KH, Li D, Jin X, Xiong W, Feng D. PMID: 41852923 [PubMed]
	Corrigendum to "Stigma experiences among young and middle-aged testicular cancer survivors in China: A phenomenological study" [Asia Pac J Oncol Nurs 13 (2026) 100825]. Asia Pac J Oncol Nurs Zhao Y, Li D, Zhang M, Yan W, Shen H, Xu M, Liu Y. PMID: 41852758 [PubMed]
	Dyadic coping, relationship quality, and psychosocial adaption between couples facing prostate cancer: A longitudinal cross-lagged study. Asia Pac J Oncol Nurs Yuan X, Chen M, Zhang T, Sun Z, Yang Z, Yin H, Yang Y. PMID: 41852754 [PubMed]
	Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis. Int J Urol Iwamoto H, Hori T, Inaba T, Nakagawa R, Kamijima T, Kano H, Makino T, Naito R, Yaegashi H, Nohara T, Shigehara K, Izumi K, Mizokami A. PMID: 41852124 [PubMed - indexed for MEDLINE]
	Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study. Prostate Cancer Prostatic Dis Shore ND, George DJ, Khan N, Constantinovici N, Chen G, Ghadessi M, Hlebec V, Morgans AK. PMID: 41851476 [PubMed - as supplied by publisher]
	Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol Padhani AR, Carlsson S, Bratt O, Schoots IG. PMID: 41850940 [PubMed - as supplied by publisher]
	The Impact of Early Postoperative Urinary Incontinence on Presenteeism After Robot-Assisted Radical Prostatectomy for Prostate Cancer: A Prospective Cohort Study. Low Urin Tract Symptoms Nakayama N, Tsuji T, Kumagai A. PMID: 41850893 [PubMed - indexed for MEDLINE]
	Detecting Distant Metastases in Prostate Cancer Using Whole-body MR Imaging Together with DWIBS (Diffusion-weighted Imaging with Background Body Signal Suppression). Magn Reson Med Sci Nakanishi K, Tanaka J, Tanaka Y, Yano K, Hongyo H, Maeda N, Sakai M, Tateishi S, Yamane Y, Kashiwagi N, Konishi K, Nagahara A, Nakayama M, Nishimura K, Takenaka S, Okada A, Kudo A, Yuzawa T, Tomiyama N. PMID: 41850822 [PubMed - as supplied by publisher]
	Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study. Actas Urol Esp (Engl Ed) Feltes Benítez N, Couñago F, Paredes-Rubio S, Peleteiro Higuero P, Molina Osorio JG, Folgar Torres A, Aissati A, Mera A, Pastor Peidró JR, Garrido Botella MI, González de Dueñas M, Duque-Santana V, Torices Caballero J, Pons Sánchez A, Andreescu Yagüe J, Rodríguez Pérez A, Guardado González S, Fernández Alonso S, Lazo-Prados A, Gaztañaga Boronat M, Moreno López S, Méndez Villamón A, García Gómez R, Gil Restrepo C, Alonso Martínez P, Mesa López F, Ibáñez Villoslada C, Willisch Santamaría P, Ribeiro I, Nicolás Boluda C, Fernández López J, López Campos F, Sargos P, González Del Portillo E. PMID: 41850565 [PubMed - as supplied by publisher]
	Editorial Comment: "Mental Health Burden of a Testicular Cancer Diagnosis: Insights from a Large Claims Database". Urology Callahan DM, Laviana AA. PMID: 41850338 [PubMed - as supplied by publisher]
	Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol Chang JCW, Nandakumar S, Stopsack KH, Fong C, Pichotta K, Jee J, Woo HJ, Donoghue MTA, Vasselman S, Barnett E, Autio KA, Danila D, McHugh D, Morris M, Rathkopf D, Scher H, Slovin S, Kantoff P, Gopalan A, Solit DB, Wibmer A, Schultz N, Abida W. PMID: 41849730 [PubMed - indexed for MEDLINE]
	Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer. J Clin Oncol Valle LF, Calais J, Kishan AU. PMID: 41849721 [PubMed - as supplied by publisher]
	Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer. J Clin Oncol Bölek H, Ürün Y. PMID: 41849717 [PubMed - as supplied by publisher]
	Applying multimodal dendrimers for prostate cancer theranostics. Nanomedicine (Lond) Lesniak WG, Pomper MG. PMID: 41849182 [PubMed - as supplied by publisher]
	Urine culture-guided antibiotic prophylaxis reduces febrile pyelonephritis after ureteral stent removal following radical cystectomy. World J Urol Kitano H, Watanabe E, Tadera K, Nakano Y, Tasaka S, Yukihiro K, Okazaki M, Nomura N, Hatayama T, Shikuma H, Iwane K, Tasaka R, Kohada Y, Takemoto K, Miyamoto S, Naito M, Kobatake K, Sekino Y, Goto K, Goriki A, Hieda K, Hayashi T, Kashiyama S, Ohge H, Hinata N. PMID: 41848879 [PubMed - indexed for MEDLINE]
	Use of MRI in the diagnosis of bladder cancer: a health economic analysis. BJU Int Sathianathen N, Perera M, Ischia J, Lawrentschuk N, Bolton D. PMID: 41848524 [PubMed - as supplied by publisher]
	Role of urinary leukocytes in the risk stratification of prostate cancer using nonlinear stacking learning strategy: a bi-cohort diagnostic study. Front Oncol Xia S, Ran Z, Cheng M, Zhu H, Yang C, Wu X. PMID: 41847692 [PubMed]
	Correlation of mRENAL score with clinical outcomes after CT-guided renal cell carcinoma cryoablation: A retrospective observational study. Qatar Med J Elhissi M, Musa E, Alahmad YM, Alaani A, Omar A, Elmajdoub A, Al-Rumaihi K, Alturkistani H, Alahmad MAM, Barah A. PMID: 41847204 [PubMed]
	Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer. Pathol Oncol Res Váradi M, Magyar B, Széles Á, Korda S, Németh B, Simon B, Reis H, Oláh C, Horváth O, Dér B, Nyirády P, Szarvas T. PMID: 41846864 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 176920

Seite 1 von 8846

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung